Nectar Life Sciences Limited — Cefuroxime Exporter Profile
Indian Pharmaceutical Exporter · #6 for Cefuroxime · $4.0M export value · DGFT Verified
Nectar Life Sciences Limited is the #6 Indian exporter of Cefuroxime with $4.0M in export value and 120 verified shipments. Nectar Life Sciences Limited holds a 3.1% market share in Cefuroxime exports across 17 countries. The company exports 3 pharmaceutical products worth $13.3M across 1 therapeutic categories.
Nectar Life Sciences Limited — Cefuroxime Export Profile: Buyers & Destinations
Where Does Nectar Life Sciences Limited Export Cefuroxime?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PHILIPPINES | $743.3K | 24 | 25.5% |
| ISRAEL | $307.7K | 15 | 10.6% |
| AUSTRALIA | $300.0K | 6 | 10.3% |
| NAMBIA | $185.7K | 12 | 6.4% |
| ZIMBABWE | $172.9K | 11 | 5.9% |
| PERU | $159.4K | 4 | 5.5% |
| MACEDONIA,THE FORMER YUGOSLAV REPUBLIC OF | $158.7K | 8 | 5.5% |
| NAMIBIA | $156.4K | 4 | 5.4% |
| COLOMBIA | $147.3K | 6 | 5.1% |
| SUDAN | $107.9K | 3 | 3.7% |
Nectar Life Sciences Limited exports Cefuroxime to 19 countries. The largest destination is PHILIPPINES accounting for 25.5% of Nectar Life Sciences Limited's Cefuroxime shipments, followed by ISRAEL (10.6%) and AUSTRALIA (10.3%). These destinations reflect Nectar Life Sciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Cefuroxime from Nectar Life Sciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CITIBANK, N.A. | PHILIPPINES | $338.3K | 7 |
| BIOAVENIR | ISRAEL | $307.7K | 15 |
| ASPEN PHARMACARE AUSTRALIA | AUSTRALIA | $250.0K | 5 |
| BANK OF THE PHILIPPINE ISLANDS (HEA | PHILIPPINES | $210.7K | 5 |
| COSPHARM INVESTMENTS | NAMBIA | $200.5K | 11 |
| THEFAR SAC | PERU | $144.2K | 3 |
| SEASONS PHARMACEUTICALS PVT LTD | ZIMBABWE | $117.9K | 6 |
| M/S.AMIPHARMA LABORATORIES LTD. | SUDAN | $107.9K | 3 |
| ALKALOID AD SKOPJE, | MACEDONIA,THE FORMER YUGOSLAV REPUBLIC OF | $100.1K | 6 |
| TCHAIKAPHARMA HIGH | BULGARIA | $75.3K | 4 |
Nectar Life Sciences Limited supplies Cefuroxime to 46 buyers globally. The largest buyer is CITIBANK, N.A. (PHILIPPINES), followed by BIOAVENIR (ISRAEL) and ASPEN PHARMACARE AUSTRALIA (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Cefuroxime Export Value and How Much Does Nectar Life Sciences Limited Contribute?
India exported $82.9M worth of Cefuroxime through 6,961 shipments from 440 suppliers to 150 countries, serving 1,458 buyers globally. Nectar Life Sciences Limited contributes $4.0M to this total, accounting for 3.1% of India's Cefuroxime exports. Nectar Life Sciences Limited ships Cefuroxime to 19 countries through 46 buyers.
What Is the Average Shipment Value for Nectar Life Sciences Limited's Cefuroxime Exports?
Nectar Life Sciences Limited's average Cefuroxime shipment value is $33.4K per consignment, based on 120 shipments totaling $4.0M. The largest destination is PHILIPPINES (25.5% of Nectar Life Sciences Limited's Cefuroxime exports).
How Does Nectar Life Sciences Limited Compare to Other Indian Cefuroxime Exporters?
Nectar Life Sciences Limited ranks #6 among 440 Indian Cefuroxime exporters with a 3.1% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($18.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($16.8M), ALKEM LABORATORIES LIMITED ($11.6M). Nectar Life Sciences Limited processed 120 shipments to 17 destination countries.
What Cefuroxime Formulations Does Nectar Life Sciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| RITEMED 500 (CEFUROXIME AXETIL TABLETS U | $200.0K | 4 |
| CEFUAVENIR 500 MG (CEFUROXIME 500 MG FILM-COATED TABLETS) | $185.0K | 4 |
| ZINNAT 250 MG (CEFUROXIME AXETIL USP 250MG TABLETS) B.NO: AZTB24001 & AZTB24002 MFG. DT: JAN-2024 EXP. DT: DEC-2026TBS | $150.0K | 3 |
| INJECTION AMIROXIME 750 (CEFUROXIME FORINJECTION USP 750 MG)BATCH NO AOIA23003TO AOIA23007 MFG DATE DEC.2023 EXP DATNOS | $107.9K | 3 |
| FUROCSEM 250 (CEFUROXIME AXETIL TABLETS | $69.4K | 2 |
| CEFUAVENIR 500 MG (CEFUROXIME 500 MG FLIM COATED TABLETS) BATCH NO BCTB23001 MFG DT DEC-2023 EXP DT NOV-2025NOS | $66.2K | 3 |
| FUREXTIL(CEFUROXIME 500MG FILM-COATED TA | $58.6K | 2 |
| LIFUROX 500 (CEFUROXIME AXETIL TABLETS 500 MG) B.NO.TLTC24001 TO TLTC24002 MFG DT.JAN 2024 EXP.DT.DEC 2026NOS | $50.7K | 3 |
| CP - CEFUROXIME 250 MG CEFUROXIME AXETI | $50.0K | 1 |
| ZINNAT 250 MG (CEFUROXIME AXETIL USP 25 | $50.0K | 1 |
Nectar Life Sciences Limited exports 92 distinct Cefuroxime formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RITEMED 500 (CEFUROXIME AXETIL TABLETS U with 4 shipments worth $200.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Cefuroxime to Key Markets
What Nectar Life Sciences Limited must comply with to export Cefuroxime to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Nectar Life Sciences Limited Compare to Nearest Cefuroxime Exporters?
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | AUROBINDO PHARMA LIMITED | $8.0M | 266 | 16 | $30.1K |
| 5 | THEON PHARMACEUTICALS LIMITED | $7.5M | 586 | 8 | $12.7K |
| 6 | NECTAR LIFE SCIENCES LIMITED ★ | $4.0M | 120 | 17 | $33.4K |
| 7 | MICRO LABS LIMITED | $3.0M | 164 | 12 | $18.0K |
| 8 | INNOVA CAPTAB LIMITED | $2.8M | 172 | 10 | $16.4K |
Nectar Life Sciences Limited ranks #6 among 440 Indian Cefuroxime exporters. Average shipment value of $33.4K compared to the market average of $188.4K. The closest competitors by value are AUROBINDO PHARMA LIMITED and THEON PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Cefuroxime Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 707 | 10.2% |
| SAHAR AIR | 670 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 661 | 9.5% |
| HYDERABAD ICD | 316 | 4.5% |
| DELHI AIR | 312 | 4.5% |
| DELHI AIR CARGO ACC (INDEL4) | 300 | 4.3% |
| JNPT/ NHAVA SHEVA SEA | 281 | 4.0% |
| HYDERABAD ICD (INSNF6) | 278 | 4.0% |
What Other Advanced Antibiotics Products Does Nectar Life Sciences Limited Export?
Nectar Life Sciences Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Nectar Life Sciences Limited's Cefuroxime Exports
The current geopolitical landscape presents significant challenges for Indian pharmaceutical exporters like Nectar Life Sciences Limited. The Israel-Iran conflict has led to disruptions in Middle East trade routes, particularly affecting the Red Sea and Suez Canal. These disruptions have resulted in increased shipping costs and extended transit times, posing risks to the timely delivery of pharmaceutical products. The Pharmaceutical Export Promotion Council of India (Pharmexcil) estimates potential losses ranging from ₹2,500 crore to ₹5,000 crore due to these supply chain issues.
In the United States, recent tariff implementations have introduced additional complexities. In August 2025, the U.S. imposed broad tariffs on imports from over 60 countries, including India, with rates reaching up to 39%. These tariffs have significantly impacted Indian pharmaceutical exports, as the U.S. is a major market for generic drugs. The Federation of Indian Export Organisations highlighted that nearly 55% of India's exports to the U.S. are affected, leading to concerns about competitiveness and market access.
Conversely, the India–EFTA Trade and Economic Partnership Agreement (TEPA), effective from October 2025, offers a positive development. This agreement aims to eliminate or reduce tariffs on goods traded between India and EFTA countries (Iceland, Liechtenstein, Norway, and Switzerland), potentially opening new avenues for Indian pharmaceutical exports. However, compliance with stringent EU regulations, such as the Falsified Medicines Directive, remains a critical factor for market entry.
Nectar Life Sciences Limited — Regulatory Compliance & Quality Standards
The regulatory environment for Indian pharmaceutical exporters is becoming increasingly stringent. The U.S. Food and Drug Administration (FDA) has intensified inspections, with over 200 conducted in 2023 and plans to increase this number in 2024. Compliance with Good Manufacturing Practices (GMP) is paramount, as non-compliance can lead to import alerts and suspension of product registrations.
Nectar Life Sciences Limited's recent regulatory setbacks, including the AEMPS' Statement of Non-Compliance and the environmental penalty imposed by the National Green Tribunal, underscore the importance of robust quality assurance systems and environmental compliance. Addressing these issues is crucial for the company to maintain and expand its export markets.
About Nectar Life Sciences Limited
Nectar Life Sciences Limited exports 3 products worth $13.3M. Beyond Cefuroxime, top products include Ceftriaxone, Cefixime. View the complete Nectar Life Sciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Cefuroxime — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Cefuroxime shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Nectar Life Sciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 134 individual customs records matching Nectar Life Sciences Limited exporting Cefuroxime, covering 92 formulations to 19 countries via 46 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 150+ countries, 1,458+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Cefuroxime Export Data from Nectar Life Sciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Nectar Life Sciences Limited's Cefuroxime exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Nectar Life Sciences Limited
Full Company Profile →
3 products · $13.3M total trade · 1 categories
Cefuroxime Stats
Company Overview
Top Products by Nectar Life Sciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Nectar Life Sciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Cefuroxime. For current shipment-level data, contact TransData Nexus.